Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Eustace, Alex J ^a   Crown, John ^a,b   Clynes, Martin ^a   O'Donovan, Norma ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DOCETAXEL; EPHRIN RECEPTOR A2; EPIRUBICIN; FOCAL ADHESION KINASE; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DACARBAZINE; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE P60; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA; PROTEIN EXPRESSION; WESTERN BLOTTING; CANCER INVASION; CELL CYCLE; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DACARBAZINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIDINES; PYRIMIDINES; RECEPTOR, EPHA2; THIAZOLES;

EID: 54349085882     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-53     Document Type: Article

References (29)

1. Gogas HJ Kirkwood JM Sondak VK Chemotherapy for metastatic melanoma: time for a change? Cancer 2007, 109(3):455-464 10.1002/cncr.22427 17200963
2. Quirt I Verma S Petrella T Bak K Charette M Temozolomide for the treatment of metastatic melanoma: A systematic review Oncologist 2007, 12(9):1114-1123 10.1634/theoncologist.12-9-1114 17914081
3. Sharma A Trivedi NR Zimmerman MA Tuveson DA Smith CD Robertson GP Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors Cancer Res 2005, 65(6):2412-2421 10.1158/ 0008-5472.CAN-04-2423 15781657
4. Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis Br J Cancer 2006, 95(5):581-586 10.1038/sj.bjc.6603291 16880785
5. Flaherty KT Sorafenib: Delivering a targeted drug to the right targets Expert Rev Anticancer Ther 2007, 7(5):617-626 10.1586/14737140.7.5.617 17492926
6. Homsi J Cubitt C Daud A The Src signaling pathway: A potential target in melanoma and other malignancies Expert Opin Ther Targets 2007, 11(1):91-100 10.1517/14728222.11.1.91 17150037
7. Barnekow A Paul E Schartl M Expression of the c-src protooncogene in human skin tumors Cancer Res 1987, 47(1):235-240 2431764
8. Marchetti D Parikh N Sudol M Gallick GE Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells Oncogene 1998, 16(25):3253-3260 10.1038/ sj.onc.1201877 9681823
9. Huang J Asawa T Takato T Sakai R Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma J Biol Chem 2003, 278(48):48367-48376 10.1074/jbc.M308213200 13129922
10. Qi J Wang J Romanyuk O Siu CH Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells Mol Biol Cell 2006, 17(3):1261-1272 1382315 16371504 10.1091/mbc.E05-10-0927
11. Wellbrock C Weisser C Geissinger E Troppmair J Schartl M Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling J Biol Chem 2002, 277(8):6443-6454 10.1074/jbc.M110684200 11734563
12. Loganzo F Jr Dosik JS Zhao Y Vidal MJ Nanus DM Sudol M Albino AP Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma Oncogene 1993, 8(10):2637-2644 7690926
13. Lombardo LJ Lee FY Chen P Norris D Barrish JC Behnia K Castaneda S Cornelius LA Das J Doweyko AM Discovery of -(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl) -piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 2004, 47(27):6658-6661 10.1021/ jm049486a 15615512
14. Nam S Kim D Cheng JQ Zhang S Lee JH Buettner R Mirosevich J Lee FY Jove R Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells Cancer Res 2005, 65(20):9185-9189 10.1158/ 0008-5472.CAN-05-1731 16230377
15. Finn RS Dering J Ginther C Wilson CA Glaspy P Tchekmedyian N Slamon DJ Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 2007, 105(3):319-326 10.1007/s10549-006-9463-x 17268817
16. Martin A Clynes M Acid phosphatase: Endpoint for in vitro toxicity tests In Vitro Cell Dev Biol 1991, 27A(3 Pt 1):183-184 10.1007/BF02630912 2033016
17. Glynn SA Gammell P Heenan M O'Connor R Liang Y Keenan J Clynes M A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin Br J Cancer 2004, 91(10):1800-1807 10.1038/sj.bjc.6602221 15505620
18. Song L Morris M Bagui T Lee FY Jove R Haura EB Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival Cancer Res 2006, 66(11):5542-5548 10.1158/0008-5472.CAN-05-4620 16740687
19. Johnson FM Saigal B Talpaz M Donato NJ Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells Clin Cancer Res 2005, 11(19 Pt 1):6924-6932 10.1158/ 1078-0432.CCR-05-0757 16203784
20. Tsao AS He D Saigal B Liu S Lee JJ Bakkannagari S Ordonez NG Hong WK Wistuba I Johnson FM Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol Cancer Ther 2007, 6(7):1962-1972 10.1158/1535-7163.MCT-07-0052 17620427
21. Becker JC Brocker EB Schadendorf D Ugurel S Imatinib in melanoma: A selective treatment option based on KIT mutation status? J Clin Oncol 2007, 25(7):e9 10.1200/JCO.2006.08.9664 17327598
22. Ugurel S Hildenbrand R Zimpfer A La Rosee P Paschka P Sucker A Keikavoussi P Becker JC Rittgen W Hochhaus A Lack of clinical efficacy of imatinib in metastatic melanoma Br J Cancer 2005, 92(8):1398-1405 10.1038/sj.bjc.6602529 15846297
23. Curtin JA Busam K Pinkel D Bastian BC Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 2006, 24(26):4340-4346 10.1200/JCO.2006.06.2984 16908931
24. Serrels A Macpherson IR Evans TR Lee FY Clark EA Sansom OJ Ashton GH Frame MC Brunton VG Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib Mol Cancer Ther 2006, 5(12):3014-3022 10.1158/ 1535-7163.MCT-06-0382 17148760
25. Luo FR Barrett YC Yang Z Camuso A McGlinchey K Wen ML Smykla R Fager K Wild R Palme H Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCELtrade mark), a multi-targeted kinase inhibitor Cancer Chemother Pharmacol 2008 18301894
26. Parsons JT Focal adhesion kinase: The first ten years J Cell Sci 2003, 116(Pt 8):1409-1416 10.1242/jcs.00373 12640026
27. Bantscheff M Eberhard D Abraham Y Bastuck S Boesche M Hobson S Mathieson T Perrin J Raida M Rau C Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotechnol 2007, 25(9):1035-1044 10.1038/nbt1328 17721511
28. Huang F Reeves K Han X Fairchild C Platero S Wong TW Lee F Shaw P Clark E Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection Cancer Res 2007, 67(5):2226-2238 10.1158/0008-5472.CAN-06-3633 17332353
29. Parri M Buricchi F Giannoni E Grimaldi G Mello T Raugei G Ramponi G Chiarugi P EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to rho-dependent actino/myosin contractility J Biol Chem 2007, 282(27):19619-19628 10.1074/jbc.M701319200 17449913